| Literature DB >> 30062609 |
Zipeng Lu1,2, Maximilian Weniger2, Kuirong Jiang1, Stefan Boeck3, Kai Zhang1, Alexander Bazhin2, Yi Miao4, Jens Werner2, Jan G D'Haese2.
Abstract
Abundant tumor stroma is a hallmark of pancreatic ductal adenocarcinoma (PDAC), and is suggested to play a role in the resistance of this deadly disease to systemic treatment. Despite promising results from preclinical studies, clinical trials with therapies targeting the tumor stroma and the vascular endothelial growth factor (VEGF) and its receptor VEGFR yielded conflicting results. With this systematic review and meta-analysis, we aim to summarize the existing evidence in this important field with a special focus on anti-VEGF/VEGFR therapy. A total of 24 clinical studies were included in the qualitative synthesis, and six randomized controlled trials (RCTs) investigating anti-VEGF/VEGFR agents were further included in the quantitative synthesis. The qualitative synthesis revealed a treatment advantage of combined therapy with nab-paclitaxel, while the meta-analysis on anti-VEGF/VEGFR drugs demonstrated marginal improvement of objective response rates and progression-free survival, but not overall survival. Stroma targeting is a promising and rapidly-developing treatment strategy in PDAC. However, novel drugs balancing stroma depletion and modulation are needed.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30062609 DOI： 10.1007/s11523-018-0578-x
Source DB: PubMed Journal: Target Oncol ISSN： 1776-2596 Impact factor: 4.493